Search Result

Results for "

inward current

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Autophagy (2) Bacterial (1) Calcium Channel (7) HCN Channel (2) iGluR (1) Isotope-Labeled Compounds (2) mGluR (1) Potassium Channel (5) Sodium Channel (13) Topoisomerase (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (16) Infection (1) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108608

o-3M3FBS	Others	Others
o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca ²⁺]_i in an agonistic manner .

HY-19434

trans-ACPD Trans-(±)-ACP	mGluR	Metabolic Disease
trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.

HY-N6868

Dimethyl lithospermate B dmLSB	Sodium Channel	Cardiovascular Disease
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

HY-116072

Antiarrhythmic agent-2	Calcium Channel	Cardiovascular Disease
Antiarrhythmic agent-2 is a nonspecific Ca ²⁺ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias .

HY-N4309

Lotusine	Others	Cardiovascular Disease
Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .

HY-W010950A

Flecainide hydrochloride	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .

HY-W010950

Flecainide	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-N4309A

Lotusine hydroxide	Others	Cardiovascular Disease
Lotusine (hydroxide) is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine (hydroxide) shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .

HY-107757

GMQ	Sodium Channel	Neurological Disease
GMQ is a ASIC (acid-sensing ion) channel activator with an EC₅₀ value of 1.83 mM for ASIC3 at pH 7.4. GMQ opens only ASIC3 but no other ASICs at pH 7.4. GMQ can be used for neurological disease research .

HY-17401

Ranolazine dihydrochloride 3 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-12533

Disopyramide 1 Publications Verification Dicorantil; SC-7031	Sodium Channel Potassium Channel	Cardiovascular Disease
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .

HY-12533A

Disopyramide phosphate Dicorantil phosphate; SC-7031 phosphate
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .

HY-B0280

Ranolazine 3 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-dd₈ dihydrochloride; RS 43285-d₈	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-13422

Zatebradine hydrochloride 1 Publications Verification UL-FS-49; UL-FS-49CL	HCN Channel	Cardiovascular Disease
Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC₅₀ values 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC₅₀ values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .

HY-112544

IK1 inhibitor PA-6 1 Publications Verification PA-6	Potassium Channel	Cardiovascular Disease
IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potent I_K1 (K_IR2.x ion-channel-carried inward rectifier current) inhibitor, with IC₅₀ values of 12-15 nM for human and mouse K_IR2.x currents. IK1 inhibitor PA-6 (PA-6) elevates K_IR2.1 protein expression and induces intracellular K_IR2.1 accumulation. IK1 inhibitor PA-6 (PA-6) has the potential to treat atrial fibrillation and arrhythmia .

HY-13422A

Zatebradine 1 Publications Verification UL-FS-49 free base; UL-FS-49CL free base	HCN Channel	Cardiovascular Disease
Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC₅₀ value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC₅₀ values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .

HY-A0170

Trovafloxacin 1 Publications Verification
Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-103399

Trovafloxacin mesylate 1 Publications Verification	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-12882A

Ifenprodil tartrate 3 Publications Verification	iGluR Potassium Channel	Neurological Disease
Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator .

Egg Laying Hormone, aplysia	Peptides	Neurological Disease
Egg Laying Hormone, aplysia is a neuropeptide synthesized by the bag cell neurons, which contains 36 amino acids and can stimulate egglaying and ovulation in Aplysia via electrical discharge triggering of neurons. Egg-laying hormone of Aplysia induces a voltage-dependent slow inward current carried by Na' in an identified motoneuron .

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6868

Dimethyl lithospermate B dmLSB	Cardiovascular Disease Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields	Sodium Channel
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

HY-N4309A

Lotusine hydroxide	Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Phenols Polyphenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Disease Research Fields Nymphaeaceae	Others
Lotusine (hydroxide) is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine (hydroxide) shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .

HY-12882A

Ifenprodil tartrate 3 Publications Verification	Alkaloids Piperidine Alkaloids Classification of Application Fields Neurological Disease Source classification Crassulaceae Sedum sarmentosum Bunge Plants Disease Research Fields	iGluR Potassium Channel
Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator .

HY-N4309

Lotusine	Cardiovascular Disease Alkaloids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields	Others
Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

inward current

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products